Pfizer Shows Off Phase III Breast Cancer Data
The data will be presented today as an oral presentation at the 2017 San Antonio Breast Cancer Symposium. Source: BioSpace
Biotech Hedge Fund Titan, Isaly, Steps Down Amid Sexual Harassment Claims
In the wake of sexual harassment allegations, OrbiMed Advisors' founder and managing partner Sam Isaly has stepped down from his position. Source: BioSpace
ThromboGenics Struggles to Find Patients for Phase II Eye Disease Trial
Resources redirected to progress new drug candidates to clinic in H1 2018. Source: BioSpace
SteadyMed Announces FDA Agreed Pathway to Trevyent NDA Resubmission
No clinical trials are required for the NDA resubmission. Source: BioSpace
Aeterna Zentaris Interim CFO Departs, Effective Immediately
The Company is currently reviewing its resource requirements with respect to its finance department and has commenced a search for Mr. Whitnell's replacement as principal financial officer. Source: BioSpace
Ex-Genentech Employees' Denali Breaks 2017 IPO Records, Raises $250M
With the raise, the company's market valuation is currently $1.7B. Source: BioSpace
Sweden's Active Biotech is Strapped for Cash and May Not Survive 2018
The Board has also decided to sell the company's property in Lund as a possible way of generating additional liquidity for the company. Source: BioSpace
Mysterious NuBiyota Inks Lease for Former Pfizer Campus
The former Pfizer campus in New York's Hudson Valley owned by Industrial Realty Group has gained a new tenant. Source: BioSpace
ERYTECH's Lead AML Drug Flunks Phase II Test
The study enrolled a total of 123 patients at 30 European sites. Source: BioSpace
Fully Loaded With Nearly 500 Employees in Rockville, GlaxoSmithKline Chief Lays Out 2018 Goals
Glaxo has a bold future planned for its R&D facility in Maryland. Source: BioSpace
- Go to the previous page
- 1
- …
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- …
- 288
- Go to the next page